Prexasertib - Acrivon Therapeutics/SOM Biotech
Alternative Names: ACR 368; Captisol® enabled prexasertib; LY 2606368 MsOH H2O; LY-2606368; Prexasertib Mesylate Monohydrate - Acrivon Therapeutics/ SOM BiotechLatest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator Array BioPharma; Eli Lilly and Company
- Developer Acrivon Therapeutics; Children's Oncology Group; Dana-Farber Cancer Institute; Eli Lilly and Company; Ewha Womans University; National Cancer Institute (USA); SOM Biotech
- Class Antineoplastics; Antivirals; Nitriles; Pyrazines; Pyrazoles; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors; Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bladder cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Phase I/II Urogenital cancer
- No development reported COVID 2019 infections
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 13 Sep 2024 Efficacy and adverse events data from a phase I/II trial in Ovarian cancer, endometrial cancer and Urogenital cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 12 Sep 2024 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Recurrent) in USA (IV) (NCT06597565)
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in South Korea (IV)